Testing a points score to predict 30-day survival
Part of Cancer clinical trials.
This study checks whether a prediction “points score” can estimate the chance of being alive 30 days after a person is referred for comfort-focused radiation therapy. It may help doctors choose the most helpful next steps and better plan follow-up care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Be able to sign consent paperwork in writing
- Have a cancer diagnosis and be referred to Radiation Oncology for palliative (comfort-focused) radiation
- You can join even if you choose not to get radiation or you’re not recommended for it
- If you start palliative radiation, you can still join even if you stop early
- Be able to do follow-up visits or phone/video check-ins
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a focused, high-precision type of radiation can control many cancer spread-out spots (“metastases”) at the same time, while keeping side effects acceptable. It may help people with many metastases live longer or have better disease control by aiming treatment at every treatable spot.
This trial tests a precise, high-dose radiation technique (SABR) for people whose cancer has started to grow again in only a few spots despite ongoing medication. The goal is to control those new growths while continuing your current treatment.
This study tests how well new computer methods (called algorithms and machine learning) can support radiation therapy decisions. You might benefit by helping improve how radiation is planned and checked, especially for cancers treated with curative-intent therapy.
This study looks at how physical activity (movement during the day) and a clinician-rated “day-to-day function” score relate to overall survival in people with certain cancers. It may help doctors understand who benefits most from activity-focused care and better monitoring.
This trial tests if a special imaging analysis can predict where your cancer might spread. It's for people with advanced lung, colorectal, or breast cancer who are starting or continuing treatment.
This study checks how acceptable, appropriate, and easy to use a metastatic breast-cancer “prognostic calculator” is for clinicians. It may help clinicians use the tool in real practice to support care decisions for people with metastatic breast cancer.
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.